ARS-CoV-2 and its related illness, COVID-19, can affect the lungs and several other organs, even in people who do not experience the “cytokine storm.” Specifically, the brain is susceptible to injury after COVID-19, and studies suggest an increased risk of large-vessel stroke and multiple vascular-territory–related infarcts, for example.1–3 Of substantial concern, people may struggle with residual “long-haul” COVID-19 symptoms for weeks or months. Carfì and colleagues4 reported that more than 80% of 143 patients admitted to hospital with acute COVID-19 experienced at least 1 persistent symptom at 36 days after discharge. A larger study showed that 76% of 1655 patients admitted to hospital reported at least 1 symptom 186 days after discharge.5

Long-haul COVID-19 symptoms strongly suggest an impact on the brain, either directly or indirectly. Electronic health records from 62 health care organizations and more than 200 000 COVID-19 survivors identified that 1 in 3 people were diagnosed with neurologic or psychiatric conditions in the months after infection.6 In a systematic review involving almost 48 000 COVID-19 survivors, commonly reported symptoms included fatigue (58%), headache (44%), attention disorder (27%) and dyspnea (24%).7 Those with long-haul symptoms may experience serious symptoms for more than 6 months. In an international survey estimating the prevalence of symptoms over 7 months after the onset of illness, 45% of the 3762 respondents reported working at a reduced level compared to before their illness, and 22% were no longer working because of health issues.8

Background: The detailed extent of neuroinvasion or deleterious brain changes resulting from COVID-19 and their time courses remain to be determined in relation to “long-haul” COVID-19 symptoms. Our objective is to determine whether there are alterations in functional brain imaging measures among people with COVID-19 after hospital discharge or self-isolation.

Methods: This paper describes a protocol for NeuroCOVID-19, a longitudinal observational study of adults aged 20–75 years at Sunnybrook Health Sciences Centre in Toronto, Ontario, that began in April 2020. We aim to recruit 240 adults, 60 per group: people who contracted COVID-19 and were admitted to hospital (group 1), people who contracted COVID-19 and self-isolated (group 2), people who experienced influenza-like symptoms at acute presentation but tested negative for COVID-19 and self-isolated (group 3, control) and healthy people (group 4, control). Participants are excluded based on premorbid neurologic or severe psychiatric illness, unstable cardiovascular disease, and magnetic resonance imaging (MRI) contraindications. Initial and 3-month follow-up assessments include multiparametric brain MRI and electroencephalography. Sensation and cognition are assessed alongside neuropsychiatric assessments and symptom self-reports. We will test the data from the initial and follow-up assessments for group differences based on 3 outcome measures: MRI cerebral blood flow, MRI resting state fractional amplitude of low-frequency fluctuation and electroencephalography spectral power.

Interpretation: If neurophysiologic alterations are detected in the COVID-19 groups in our NeuroCOVID-19 study, this information could inform future research regarding interventions for long-haul COVID-19. The study results will be disseminated to scientists, clinicians and COVID-19 survivors, as well as the public and private sectors to provide context on how brain measures relate to lingering symptoms.
The time course of recovery from brain-related long-haul COVID-19 symptoms remains poorly understood. We developed an experimental protocol (NeuroCOVID-19) using multimodality assessments to assess and characterize COVID-19 brain changes after a hospital stay or self-isolation for COVID-19. The protocol aims to test the primary hypothesis that groups with COVID-19 show altered brain function, as reflected by vascular and physiologic functional brain measures in relation to control groups. A second hypothesis posits group differences in these functional brain measures between the initial and 3-month follow-up assessments.

Methods

Study design and setting

This is a protocol for a longitudinal observational study (NeuroCOVID-19) that aims to recruit 240 adults in equal numbers of males and females. The study began in April 2020.

We will conduct a suite of neurologic tests in participants at the initial assessment and at 3-month follow-up at Sunnybrook Health Sciences Centre, Toronto, Ontario, or remotely via an online meeting platform (depending on the test). Sunnybrook Health Sciences Centre is a large academic hospital housing a research institute with extensive research-dedicated equipment and resources, and is fully affiliated with the University of Toronto. Baycrest Health Sciences is a secondary site for data collection.

The participants are categorized into 4 groups of 60 participants: people who contracted COVID-19 and were admitted to Sunnybrook Health Sciences Centre (group 1), people who contracted COVID-19 and self-isolated (group 2), people who experienced influenza-like symptoms at acute presentation but tested negative for COVID-19 and self-isolated (group 3, control) and healthy people (group 4, control). There is no upper bound on the time lapse between infection and the baseline research visit for the COVID-19 groups because of the need to capture a spectrum of long-haul symptoms and to collect an inclusive sample. Group 3 participants are assessed within 150 days of their infection. Group 4 participants are recruited to match the other 3 groups on sex, gender and 3 expected age categories (20–39 yr, 40–59 yr and 60–75 yr).

At the initial and 3-month follow-up assessments, brain imaging is performed, and sensory tests, a cognitive test battery and a memory test are administered on site (Table 1). Research staff and participants abide by the hospital infection prevention and control requirements. An emotion test battery, assessment of neuropsychiatric symptoms and self-report questionnaire assessment are administered remotely at baseline and 3-month follow-up.

Participants

Participants are eligible for inclusion if they are aged 20–75 years and living independently. People are excluded if they have a diagnosis of previous dementia, neurologic disorder, severe psychiatric illness, traumatic brain injury or ongoing unstable cardiovascular disease, or contraindication to magnetic resonance imaging (MRI) (e.g., ferromagnetic implant). Contrast-enhanced MRI is not performed in people with poor kidney function (estimated glomerular filtration rate < 60 mL/min per 1.73 m^2) or at follow-up.

Potentially eligible participants are identified through the emergency department electronic database at Sunnybrook Health Sciences Centre, which is queried weekly by a research staff member. Physicians on the research team are able to facilitate recruitment by helping to identify potentially eligible people. We use monthly meetings, internal emails and telephone calls to communicate between physician referrals and research staff. Community advertisement is being performed.

<table>
<thead>
<tr>
<th>Table 1: Summary of visit assessments for the NeuroCOVID-19 study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit no.</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4 (3-mo follow-up)</td>
</tr>
<tr>
<td>5 (3-mo follow-up)</td>
</tr>
</tbody>
</table>

Note: EEG = electroencephalography, MBI-C = Mild Behavioral Impairment Checklist, MRI = magnetic resonance imaging, NIH = National Institute of Health, NIH Toolbox = National Institutes of Health Toolbox for the Assessment of Neurological and Behavioral Function, PROMIS = Patient-Reported Outcomes Measurement Information System, SF-36 = 36-Item Short Form Survey.
through electronic posters. Potentially eligible participants are contacted by telephone or email and screened for eligibility. We obtain informed consent using ethics protocol documents delivered by email.

Data sources

COVID-19 status
A COVID-19 diagnosis is determined by a provincially approved facility through a nasopharyngeal or oropharyngeal swab and a subsequent real-time reverse transcription polymerase chain reaction test, according to Public Health Ontario procedures. Participants provide physical or electronic evidence for their test result from Public Health Ontario or mychart.ca, a service provider of hospital electronic medical information. The test information is shared as photographic evidence with a research staff member. Participants are not infectious during on-site assessments as they arrive at least 14 days after infection, report no contact with anyone with COVID-19 symptoms, and have not travelled internationally within the 14 days before the study visit.

3 T magnetic resonance imaging
Imaging of the brain is performed with the Magnetom Prisma 3 T MRI system (Siemens Healthineers). The MRI protocol includes high-resolution anatomic imaging (T₁-weighted, T₂-weighted, fluid-attenuated inversion recovery and susceptibility-weighted imaging) to identify brain lesions and permit analysis of tissue signal intensity and volume.

The following MRI sequences probe brain function. Pseudocontinuous arterial spin labelling MRI is performed with a single postlabelling delay to quantify cerebral blood flow, and resting state functional MRI is performed to evaluate the fractional amplitude of low-frequency fluctuations (fALFFs) in blood-oxygenation-level–dependent signals representative of brain activity (Table 2). Additional functional

<table>
<thead>
<tr>
<th>MRI sequence†</th>
<th>Parameters</th>
<th>Scan time, min:s</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-dimensional magnetization-prepared rapid gradient-echo (MPRAGE)</td>
<td>• TR/TE/TI = 2500/4.7/1100 ms; θ = 7°; FOV = 256 × 256 × 192 mm; 1-mm isotropic voxels</td>
<td>3:45</td>
</tr>
<tr>
<td>3-dimensional T₁-weighted fluid-attenuated inversion recovery (FLAIR)</td>
<td>• TR/TE/TI = 5000/388/1800 ms; FOV = 256 × 256 × 192 mm; 1-mm isotropic voxels</td>
<td>5:57</td>
</tr>
<tr>
<td>3-dimensional pseudocontinuous arterial spin labelling (pCASL)</td>
<td>• Label duration = 1500 ms; postlabel delay = 1800 ms</td>
<td>4:27</td>
</tr>
<tr>
<td>3-dimensional T₂-weighted sampling perfection with application-optimized contrasts using different θ evolution (SPACE)</td>
<td>• TR/TE₀ = 4100/37 ms; FOV = 240 × 240 × 120 mm; 2.5-mm isotropic voxels; 10% oversampling; Turbo factor = 14; background suppression</td>
<td>3:42</td>
</tr>
<tr>
<td>2-dimensional multislice susceptibility-weighted imaging (SWI)</td>
<td>• TR/TE = 28/20 ms; FOV = 240 × 240 × 156 mm</td>
<td>4:02</td>
</tr>
<tr>
<td>2-dimensional multislice blood-oxygenation-level–dependent (BOLD) resting state functional MRI</td>
<td>• 2-dimensional echo-planar imaging; TR/TE = 2130/30 ms; θ = 70°</td>
<td>9:00</td>
</tr>
<tr>
<td>2-dimensional multislice 3-shell diffusion-weighted imaging (DWI)</td>
<td>• TR/TE = 4300/62 ms; FOV = 240 × 240 mm; 60 slices; 2.5-mm isotropic voxels</td>
<td>8:34</td>
</tr>
<tr>
<td>Contrast agent administration</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Dynamic susceptibility contrast (DSC) MRI</td>
<td>• 2-dimensional echo-planar imaging; TR/TE = 1250/30 ms; θ = 7°; FOV = 220 × 220 × 80 mm, 1.74-mm × 1.74-mm × 4.0-mm voxels; 140 time points</td>
<td>3:07</td>
</tr>
<tr>
<td>Scanning paused</td>
<td>• Delay until 10 min after contrast administration to permit gadolinium-enhanced T₁-weighted acquisition</td>
<td>6:53</td>
</tr>
<tr>
<td>3-dimensional MPRAGE 10 min after injection</td>
<td>• As above</td>
<td>3:45</td>
</tr>
<tr>
<td>Overall</td>
<td>–</td>
<td>53:12</td>
</tr>
</tbody>
</table>

Note: θ = flip angle, FOV = field of view, MRI = magnetic resonance imaging, TE = echo time, TE₀ = effective echo time, T₁ = inversion time, TR = repetition time.

Table 2: Sequences, key acquisition parameters, sequence timing and protocol timing of magnetic resonance imaging of the brain

*Conducted with the standard head coil.
†All sequences are part of the Siemens Healthineers Magnetom Prisma 3 T MRI system with the exception of the pCASL implementation.
 imaging is included in support of the primary aims: 3-shell diffusion-weighted imaging probes neuroinflammation and tissue microstructural integrity, and dynamic susceptibility contrast MRI is performed with a common contrast agent (Gadovist [gadobutrol], Bayer) (1 mL/kg intravenously with 25 mL saline flush at a rate of 5 mL/s) to generate cerebral blood volume maps. Last, 10 minutes after contrast injection, $T_2$-weighted MRI is repeated to visualize extravasated contrast agent and potential leakiness of the blood–brain barrier.

Electroencephalography
A 4-channel wireless electroencephalography (EEG) headband (Muse, InteraXon) is used to record the EEG at rest with eyes closed (5 min) and eyes open (5 min). Details of analysis of the EEG data are provided in Appendix 1 (available at www.cmajopen.ca/content/9/4/E1114/suppl/DC1). One auditory oddball EEG task is collected as an additional exploratory test in which participants respond to infrequent target tones and ignore frequent standard tones, and during a visual perceptual task that requires discriminating a contour in a cluttered background of increasing density.

Olfaction
We use the 40-odorant University of Pennsylvania Smell Identification Test (UPSIT, Sensonics International) to characterize olfactory function relative to normative data. The test yields results ranging from normosmia to severe or total anosmia.

Vision
As COVID-19 may affect the eye or neural visual perceptual functions, the Freiburg Vision Test is administered to measure far visual acuity and vernier acuity, and binocular contrast sensitivity is measured with the Pelli–Robson contrast sensitivity test.

Cognition
The NIH (National Institutes of Health) Toolbox for the Assessment of Neurological and Behavioral Function full Cognition Battery are administered on site via an iPad app. The battery comprises 7 instruments assessing processing speed, working memory, executive function and episodic memory, which together provide composite scores of crystallized cognition and fluid cognition, and a total cognition score. We use the Mnemonic Similarity Task to assess memory, as this test is sensitive to age-related memory decline and functional brain connectivity.

Other assessments
The full NIH Emotion Battery, a modified Mild Behavioral Impairment Checklist and the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) are administered during a one-on-one online meeting on a secure Zoom platform. The PROMIS includes short-form scales to measure fatigue, dyspnea, cognitive function and sleep disturbance symptoms. General functional status is assessed with the Post-COVID-19 Functional Status scale, and the 36-Item Short Form Survey assesses health-related quality of life (Appendix 1). These data are entered directly into a REDCap database by a research staff member (X.J., E.R. or S.J.G.) and verified for accuracy by another staff member (X.J., E.R. or S.J.G.).

Statistical analysis
Using a scoring sheet adapted from a previous visual rating rubric, 2 neuroradiologists score anatomic brain MRI scans to visualize lesions of presumed vascular origin, cerebral microbleeds and inflammation in brain tissue. We expect that a proportion of people recovering from COVID-19 as well as control participants will show vascular lesions related to age and vascular risk factors on MRI. Furthermore, pathogens (e.g., bacterial, viral) can invade the central nervous system, and this may be reflected in the control participants who experienced influenza-like symptoms. Diffusion-weighted images are conducive to conventional maps of mean diffusivity or restricted diffusion. Quantitative anatomic volumetric estimation is conducted with semiautomatic Sunnybrook software as a supplementary analysis.

Electroencephalography at rest will be characterized with power spectral density across frequency bands, and we will use these measures for hypothesis testing. Additional analysis of the EEG data will include examination of signal complexity, as it is known to be sensitive to brain injury. Event-related potentials in response to auditory oddball and visual stimuli will be used to probe possible brain stem dysfunction associated with cognitive impairment and possible delays in visual perceptual processes.

Long-haul COVID-19 symptoms are characterized by olfaction, domain-specific cognitive impairment and neuropsychiatric measures. We use existing scoring methods to obtain standardized scores for olfaction, NIH Toolbox, PROMIS and 36-Item Short Form Survey measures relative to normative data. We will use a linear mixed-effects model to...
test whether longitudinal changes in these measures explain variance in cerebral blood flow, tALFF and EEG functional brain outcomes from the initial to the 3-month assessment. We will use a multiple imputation method to account for data lost to follow-up and to mitigate bias.34

Ethics approval
This study protocol was approved by the Sunnybrook Health Sciences Centre Research Ethics Board and the Baycrest Health Sciences Research Ethics Board.

Interpretation
In this longitudinal observational study assessing and characterizing COVID-19 brain changes after a hospital stay or self-isolation for COVID-19, the inclusion of participants who experienced influenza-like symptoms at acute presentation but tested negative for COVID-19 and self-isolated (group 3, control) will enable us to account for other typical viral pathogens, and the inclusion of healthy participants (group 4, control) will enable us to account for the societal effects of the pandemic.26,35,36

At the time of writing, 73 participants (8 in group 1, 50 in group 2 and 15 in group 3) had had an initial assessment, and 61 (6, 42 and 13, respectively) had completed the 3-month follow-up assessment; 3 participants declined follow-up because of MRI-related anxiety.

Ethical aspects and knowledge translation need to be considered in implementing this protocol. One ethics consideration involves incidental findings, which are likely to occur. To address brain imaging findings such as excessive cerebral microbleeds, for example, procedures have been implemented to initiate follow-up with diagnostic radiologic imaging. Clinician-researchers from the NeuroCOVID-19 team are prepared to provide clinical advice and care, as required, for participants for whom additional clinical services such as cognitive neurology or psychiatry may be warranted.

The overall implication is that the study will provide detailed characterization of the functional neuroimaging correlates of long-haul COVID-19 symptoms and subtypes, which will assist in the development and implementation of effective treatments for these conditions. To raise awareness of these research outputs among scientists, clinicians, and the public and private sectors, NeuroCOVID-19 team members will participate in academic conferences and national forums related to COVID-19, as well as news and social media outreach. Research newsletters will also convey timely information to study participants.

Knowledge exchange is possible through scientific collaboration or adoption of the protocol at other sites. For example, high-spatial-resolution 3T MRI permits more detailed characterization of brain anatomy than is achieved with typical clinical imaging. Furthermore, functional brain maps collected under a resting state will be deployed to increase sensitivity to altered brain physiology. Aspects of the sensory, behavioural and EEG tests are conducive to mobile or remote assessment.

Limitations
Diagnostic certainty of COVID-19 status is limited by the sensitivity and specificity of the polymerase chain reaction tests. Blood biomarkers of immunity status and other factors would provide important complementary information and can be added to the protocol in the future.

Recruitment bias cannot be ruled out. In addition, recruitment into the COVID-19 groups does not include an upper bound on the number of days since infection. Although this provides a more inclusive sample, the effect sizes may be reduced in the group comparisons as a consequence. The age of inclusion is wide, which introduces within-group age-related variability, but this also provides an opportunity to better understand the influence of young, mid-life and older age demographic characteristics on COVID-19 sequelae. A UK surveillance study showed that young and middle-aged COVID-19 survivors were more likely to report neuropsychiatric issues than cerebrovascular issues.37 Hence, the functional imaging measures in NeuroCOVID-19 may help to elucidate this phenomenon by age-stratified post hoc analyses.

Prepandemic brain measures, which other studies have been able to achieve,38 are not part of the current protocol.

The 3-month follow-up visit after the initial visit was a pragmatic choice to capture a recovery point that coincides roughly with 6–12 months from the time of infection for the study participants with lingering COVID-19 symptoms. The protocol can easily be extended to facilitate additional longitudinal assessments.

Conclusion
The detailed extent of neuroinvasion or deleterious brain changes resulting from COVID-19 and their time courses remain to be determined in relation to long-haul COVID-19 symptoms. The NeuroCOVID-19 protocol is designed to address this issue through innovative methodology. We expect that it will be possible to translate the knowledge gained from NeuroCOVID-19 into effective, targeted interventions for people with specific long-haul COVID-19 symptoms.

References


